49 matches for your search in the start-up spotlight
rss
DIOSynVax customises vaccine antigen design to maximise the protection that vaccines can provide worldwide against existing and future viruses. Grounded firmly in virus structure and evolution, our method is patent protected, combining computational biology with in vitro and in vivo validation, ...
Imophoron was founded in 2017 and is based at Science Creates in Bristol, UK. Imophoron has developed a novel next-generation nanoparticle platform, ADDomer™, initially focused on the development of vaccines to combat present and future infectious diseases, including ‘Disease X’ outbreaks. ...
Grey Wolf is a UK and Australian-based drug discovery and development company focused on developing novel immuno-oncology agents. The company was founded in 2017 by experienced industry professionals; Tom McCarthy (Executive Chairman; former President and CEO of Spinifex Pharmaceuticals), and ...
Rewind Therapeutics develops first-in-class therapeutics designed to re-initiate the process of remyelination in patients suffering from major debilitating diseases such as multiple sclerosis, optic neuritis or nerve injuries. A common feature of these illnesses is the loss of the myelin sheath, ...
OncoHost is a commercial-stage precision oncology company headquartered in Binyamina, Israel and Cary, NC. Led by an experienced team of entrepreneurs and industry experts and supported by a large-scale prospective clinical trial with over 35 sites worldwide, OncoHost aims to understand the ...
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in ...
Synplogen is a DNA synthesis startup spun out of Kobe University's Graduate School of Science, Technology and Innovation in February, 2017. Combining its proprietary OGAB techniques with cutting edge genetic engineering, information science and robotics, Synplogen provides a variety of services ...
T-CURX is a Biotech company, spun-out from the University Clinics Würzburg, Germany, developing first- and best-in-class personalized immunotherapies on the basis of CAR-T cells. CAR-T cells are a transformative, one-shot, chemotherapy-free targeted and personalized cancer treatment. T-CURX has ...
METiS Therapeutics is a discovery technology and therapeutics company that has the potential to drive best-in-class drug assets in a wide range of therapeutic areas. The METiS platform (AiTEM) combines state-of-the-art AI data-driven algorithms, mechanism-driven quantum mechanics and molecular ...
Mireca is a preclinical stage start-up company based in Tübingen (Germany) aiming to develop its cyclic guanosine monophosphate (cGMP) analogues for diseases with pathways showing a dysregulation of cGMP signaling, affecting the protein kinase G (PKG) pathway.
